Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort

2023; American Society for Microbiology; Volume: 61; Issue: 3 Linguagem: Inglês

10.1128/jcm.01478-22

ISSN

1098-660X

Autores

Rehan R. Syed, Donald G. Catanzaro, Rebecca E. Colman, Christopher G. Cooney, Yvonne Linger, Alexander V. Kukhtin, Rebecca C. Holmberg, Ryan Norville, Valeriu Crudu, Nelly Ciobanu, Alexandru Codreanu, Marva Seifert, Naomi Hillery, Peter G. Chiles, Antonino Catanzaro, Timothy C. Rodwell,

Tópico(s)

Pneumonia and Respiratory Infections

Resumo

While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for tuberculosis (TB) and antituberculosis drug resistance could significantly improve access to testing. In this study, we evaluated the accuracy of the Akonni Biosystems XDR-TB (extensively drug-resistant TB) TruArray and lateral-flow-cell (XDR-LFC) assay (Akonni Biosystems, Inc., Frederick, MD, USA), a novel assay that detects mutations in seven genes associated with resistance to antituberculosis drugs:

Referência(s)